Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MabThera (rituximab)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    436 result(s) found for: MabThera (rituximab). Displaying page 6 of 22.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2006-005552-33 Sponsor Protocol Number: APO3585g Start Date*: 2007-06-06
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OT...
    Medical condition: Follicular, CD20+, B-cell non-Hodgkin’s lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000209-35 Sponsor Protocol Number: 7805 Start Date*: 2016-08-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism
    Medical condition: Graves' hyperthyroidism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000211-33 Sponsor Protocol Number: P02100 Start Date*: 2016-10-06
    Sponsor Name:Papworth Hospital NHS Foundation Trust
    Full Title: Dose Effect Relationship of a Single Dose of Rituximab on the Kinetics of B Lymphocytes in Patients with Acute ST-Segment Myocardial Infarction
    Medical condition: Anterior STEMI revascularised by PPCI
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10066641 Acute myocardial infarction, of anterior wall LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002110-12 Sponsor Protocol Number: GO28667 Start Date*: 2014-02-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH...
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) FR (Completed) NL (Completed) HU (Completed) DK (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004341-17 Sponsor Protocol Number: PCYC-1123-CA Start Date*: 2014-10-16
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter Open-Label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-005543-90 Sponsor Protocol Number: 20130108 Start Date*: 2014-08-26
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004619-28 Sponsor Protocol Number: RITS-PO-2019 Start Date*: 2019-04-24
    Sponsor Name:Region Örebro län
    Full Title: Rituximab - Immunotherapy for Obsessive-Compulsive Disorder. An open pilot study.
    Medical condition: Treatment-resistant patients with Obsessive Compulsive Disorder (OCD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004618-17 Sponsor Protocol Number: RITS-PS-2019 Start Date*: 2019-04-24
    Sponsor Name:Region Örebro län
    Full Title: Rituximab - Immunotherapy for Schizophrenia spectrum disorder in adults. An open pilot study.
    Medical condition: Treatment-resistant patients with schizophrenia spectrum disorder (SSD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000413-36 Sponsor Protocol Number: BGB-3111-306 Start Date*: 2020-02-24
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Wh...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000222-51 Sponsor Protocol Number: 06_DOG05_44 Start Date*: 2007-09-07
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: Short CHemo RadioImmunotherapy in Follicular Trial of 90Y Ibritumomab tiuxetan (ZevalinTM) as therapy for first and second relapse in Follicular Lymphoma
    Medical condition: Follicular Lymphoma First and second relapse of Follicular Lymphoma grade 1, 2, 3a.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004673-98 Sponsor Protocol Number: ML 20538 Start Date*: 2006-10-16
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker
    Medical condition: To investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-004740-31 Sponsor Protocol Number: Start Date*: 2005-12-21
    Sponsor Name:University of Copenhagen
    Full Title: Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren disease
    Medical condition: Previously treated patients with primary Sjögrens disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10040767 PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004908-37 Sponsor Protocol Number: IRIS Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding...
    Medical condition: indolent CD-20 positive lymphoma of conjunctiva
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002290-19 Sponsor Protocol Number: CC-5013-NHL-008 Start Date*: 2017-12-07
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/ref...
    Medical condition: relapsed/refractory follicular, marginal zone or mantle cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023335-41 Sponsor Protocol Number: 16011 Start Date*: 2011-11-23
    Sponsor Name:Abbott
    Full Title: A Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Indolent Lymphoma
    Medical condition: Relapsed Indolent Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001666-32 Sponsor Protocol Number: APM4083g Start Date*: 2007-12-05
    Sponsor Name:Genentech Inc
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULA...
    Medical condition: Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029593 Non-Hodgkin's lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002765-34 Sponsor Protocol Number: MabionCD20-003RA Start Date*: 2021-10-21
    Sponsor Name:Mabion S.A.
    Full Title: A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20 (manufactured in commercial scale), EU-approved MabThera® and US-licen...
    Medical condition: Moderate-to-severe rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005580-95 Sponsor Protocol Number: FL2008 RGM Start Date*: 2008-09-19
    Sponsor Name:Goelams
    Full Title: An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follic...
    Medical condition: This study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with non bulky follicular non Hodgkin’s lymphoma with no prio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025310 Lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002896-40 Sponsor Protocol Number: B3281001 Start Date*: 2012-08-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGR...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002062-13 Sponsor Protocol Number: WA25615 Start Date*: 2013-01-18
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Phase IIa, International, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety and Pharmacokinetics of 4× 375 mg/m2 Intravenous Rituximab in Pediatric Patients with Severe Granul...
    Medical condition: granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis LLT
    19.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 08:13:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA